Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 117

1.

Elucidation of role of an acetyltransferase like protein in paromomycin resistance in Leishmania donovani using in silico and in vitro approaches.

Verma A, Nayek A, Kumar A, Singh R, Salotra P.

J Biomol Struct Dyn. 2019 Oct 26:1-12. doi: 10.1080/07391102.2019.1682674. [Epub ahead of print]

PMID:
31625467
2.

Artemisinin-resistant Leishmania parasite modulates host cell defense mechanism and exhibits altered expression of unfolded protein response genes.

Verma A, Ghosh S, Salotra P, Singh R.

Parasitol Res. 2019 Sep;118(9):2705-2713. doi: 10.1007/s00436-019-06404-9. Epub 2019 Jul 29.

PMID:
31359134
3.

Validation of SYBR green I based closed tube loop mediated isothermal amplification (LAMP) assay and simplified direct-blood-lysis (DBL)-LAMP assay for diagnosis of visceral leishmaniasis (VL).

Dixit KK, Verma S, Singh OP, Singh D, Singh AP, Gupta R, Negi NS, Das P, Sundar S, Singh R, Salotra P.

PLoS Negl Trop Dis. 2018 Nov 15;12(11):e0006922. doi: 10.1371/journal.pntd.0006922. eCollection 2018 Nov.

4.

Lipase Precursor-Like Protein Promotes Miltefosine Tolerance in Leishmania donovani by Enhancing Parasite Infectivity and Eliciting Anti-inflammatory Responses in Host Macrophages.

Deep DK, Singh R, Kulshrestha A, Wajid S, Salotra P.

Antimicrob Agents Chemother. 2018 Nov 26;62(12). pii: e00666-18. doi: 10.1128/AAC.00666-18. Print 2018 Dec.

5.

A Leishmania-specific gene upregulated at the amastigote stage is crucial for parasite survival.

Avishek K, Ahuja K, Pradhan D, Gannavaram S, Selvapandiyan A, Nakhasi HL, Salotra P.

Parasitol Res. 2018 Oct;117(10):3215-3228. doi: 10.1007/s00436-018-6020-6. Epub 2018 Aug 14.

PMID:
30109416
6.

Revisiting the role of the slit-skin smear in the diagnosis of Indian post-kala-azar dermal leishmaniasis.

Bhargava A, Ramesh V, Verma S, Salotra P, Bala M.

Indian J Dermatol Venereol Leprol. 2018 Nov-Dec;84(6):690-695. doi: 10.4103/ijdvl.IJDVL_970_16.

7.

A novel signal sequence negative multimeric glycosomal protein required for cell cycle progression of Leishmania donovani parasites.

Ahuja K, Beg MA, Sharma R, Saxena A, Naqvi N, Puri N, Rai PK, Chaudhury A, Duncan R, Salotra P, Nakhasi H, Selvapandiyan A.

Biochim Biophys Acta Mol Cell Res. 2018 Aug;1865(8):1148-1159. doi: 10.1016/j.bbamcr.2018.05.012. Epub 2018 May 23.

8.

Transcriptome profiling identifies genes/pathways associated with experimental resistance to paromomycin in Leishmania donovani.

Verma A, Bhandari V, Deep DK, Sundar S, Dujardin JC, Singh R, Salotra P.

Int J Parasitol Drugs Drug Resist. 2017 Dec;7(3):370-377. doi: 10.1016/j.ijpddr.2017.10.004. Epub 2017 Oct 10.

9.

Serological and Molecular Analysis of Leishmania Infection in Healthy Individuals from Two Districts of West Bengal, India, Endemic for Visceral Leishmaniasis.

Kaushal H, Bhattacharya SK, Verma S, Salotra P.

Am J Trop Med Hyg. 2017 Jun;96(6):1448-1455. doi: 10.4269/ajtmh.16-0592.

10.

Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress.

Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, Sundar S, Ramesh V, Dujardin JC, Salotra P.

PLoS Negl Trop Dis. 2017 Jun 2;11(6):e0005641. doi: 10.1371/journal.pntd.0005641. eCollection 2017 Jun.

11.

Development of a rapid loop-mediated isothermal amplification assay for diagnosis and assessment of cure of Leishmania infection.

Verma S, Singh R, Sharma V, Bumb RA, Negi NS, Ramesh V, Salotra P.

BMC Infect Dis. 2017 Mar 23;17(1):223. doi: 10.1186/s12879-017-2318-8.

12.

Indian erythrodermic postkala-azar dermal leishmaniasis.

Sethuraman G, Bhari N, Salotra P, Ramesh V.

BMJ Case Rep. 2017 Jan 27;2017. pii: bcr2016217926. doi: 10.1136/bcr-2016-217926.

13.

Gene deleted live attenuated Leishmania vaccine candidates against visceral leishmaniasis elicit pro-inflammatory cytokines response in human PBMCs.

Avishek K, Kaushal H, Gannavaram S, Dey R, Selvapandiyan A, Ramesh V, Negi NS, Dubey US, Nakhasi HL, Salotra P.

Sci Rep. 2016 Sep 14;6:33059. doi: 10.1038/srep33059.

14.

Methods to Evaluate the Preclinical Safety and Immunogenicity of Genetically Modified Live-Attenuated Leishmania Parasite Vaccines.

Gannavaram S, Bhattacharya P, Dey R, Ismail N, Avishek K, Salotra P, Selvapandiyan A, Satoskar A, Nakhasi HL.

Methods Mol Biol. 2016;1403:623-38. doi: 10.1007/978-1-4939-3387-7_35.

PMID:
27076157
15.

Evaluation of cellular immunological responses in mono- and polymorphic clinical forms of post-kala-azar dermal leishmaniasis in India.

Kaushal H, Bras-Gonçalves R, Avishek K, Kumar Deep D, Petitdidier E, Lemesre JL, Papierok G, Kumar S, Ramesh V, Salotra P.

Clin Exp Immunol. 2016 Jul;185(1):50-60. doi: 10.1111/cei.12787. Epub 2016 May 4.

16.

Correction: Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.

Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, Salotra P.

PLoS Negl Trop Dis. 2015 Dec 7;9(12):e0004289. doi: 10.1371/journal.pntd.0004289. eCollection 2015 Dec. No abstract available.

17.

Clinico-epidemiological analysis of Post kala-azar dermal leishmaniasis (PKDL) cases in India over last two decades: a hospital based retrospective study.

Ramesh V, Kaushal H, Mishra AK, Singh R, Salotra P.

BMC Public Health. 2015 Oct 26;15:1092. doi: 10.1186/s12889-015-2424-8.

18.

Decline in Clinical Efficacy of Oral Miltefosine in Treatment of Post Kala-azar Dermal Leishmaniasis (PKDL) in India.

Ramesh V, Singh R, Avishek K, Verma A, Deep DK, Verma S, Salotra P.

PLoS Negl Trop Dis. 2015 Oct 22;9(10):e0004093. doi: 10.1371/journal.pntd.0004093. eCollection 2015. Erratum in: PLoS Negl Trop Dis. 2015 Dec;9(12):e0004289.

19.

Leishmania donovani-specific Ub-related modifier-1: an early endosome-associated ubiquitin-like conjugation in Leishmania donovani.

Sharma V, Sharma P, Selvapandiyan A, Salotra P.

Mol Microbiol. 2016 Feb;99(3):597-610. doi: 10.1111/mmi.13253. Epub 2015 Nov 20.

20.

Role of CD8(+) T cells in protection against Leishmania donovani infection in healed Visceral Leishmaniasis individuals.

Kaushal H, Bras-Gonçalves R, Negi NS, Lemesre JL, Papierok G, Salotra P.

BMC Infect Dis. 2014 Dec 3;14:653. doi: 10.1186/s12879-014-0653-6.

21.

Pediatric cutaneous leishmaniasis in an endemic region in India.

Agrawal S, Khandelwal K, Bumb RA, Oghumu S, Salotra P, Satoskar AR.

Am J Trop Med Hyg. 2014 Nov;91(5):901-4. doi: 10.4269/ajtmh.13-0737. Epub 2014 Oct 6.

22.

Post-kala-azar dermal leishmaniasis in HIV-coinfected individuals: problems in diagnosis and treatment.

Ramesh V, Avishek K, Salotra P.

Int J Dermatol. 2015 Jan;54(1):116-20. doi: 10.1111/ijd.12665. Epub 2014 Sep 10. No abstract available.

PMID:
25209701
23.

Biomarkers of safety and immune protection for genetically modified live attenuated leishmania vaccines against visceral leishmaniasis - discovery and implications.

Gannavaram S, Dey R, Avishek K, Selvapandiyan A, Salotra P, Nakhasi HL.

Front Immunol. 2014 May 23;5:241. doi: 10.3389/fimmu.2014.00241. eCollection 2014. Review.

24.

Generation of growth arrested Leishmania amastigotes: a tool to develop live attenuated vaccine candidates against visceral leishmaniasis.

Selvapandiyan A, Dey R, Gannavaram S, Solanki S, Salotra P, Nakhasi HL.

Vaccine. 2014 Jun 30;32(31):3895-901. doi: 10.1016/j.vaccine.2014.05.009. Epub 2014 May 14. Review.

PMID:
24837513
25.

In vitro evaluation of a soluble Leishmania promastigote surface antigen as a potential vaccine candidate against human leishmaniasis.

Chamakh-Ayari R, Bras-Gonçalves R, Bahi-Jaber N, Petitdidier E, Markikou-Ouni W, Aoun K, Moreno J, Carrillo E, Salotra P, Kaushal H, Negi NS, Arevalo J, Falconi-Agapito F, Privat A, Cruz M, Pagniez J, Papierok GM, Rhouma FB, Torres P, Lemesre JL, Chenik M, Meddeb-Garnaoui A.

PLoS One. 2014 May 2;9(5):e92708. doi: 10.1371/journal.pone.0092708. eCollection 2014.

26.
27.

Elucidation of cellular mechanisms involved in experimental paromomycin resistance in Leishmania donovani.

Bhandari V, Sundar S, Dujardin JC, Salotra P.

Antimicrob Agents Chemother. 2014 May;58(5):2580-5. doi: 10.1128/AAC.01574-13. Epub 2014 Feb 18.

28.

Comparative transcript expression analysis of miltefosine-sensitive and miltefosine-resistant Leishmania donovani.

Kulshrestha A, Sharma V, Singh R, Salotra P.

Parasitol Res. 2014 Mar;113(3):1171-84. doi: 10.1007/s00436-014-3755-6. Epub 2014 Jan 22.

PMID:
24449447
29.

Analysis of localized immune responses reveals presence of Th17 and Treg cells in cutaneous leishmaniasis due to Leishmania tropica.

Katara GK, Raj A, Kumar R, Avishek K, Kaushal H, Ansari NA, Bumb RA, Salotra P.

BMC Immunol. 2013 Nov 22;14:52. doi: 10.1186/1471-2172-14-52.

30.

Increased parasite surface antigen-2 expression in clinical isolates of Leishmania donovani augments antimony resistance.

Bhandari V, Kumar D, Verma S, Srividya G, Negi NS, Singh R, Salotra P.

Biochem Biophys Res Commun. 2013 Nov 1;440(4):646-51. doi: 10.1016/j.bbrc.2013.09.113. Epub 2013 Oct 5.

PMID:
24103752
31.

Combination therapy with amphotericin-B and miltefosine for post-kala-azar dermal leishmaniasis: a preliminary report.

Ramesh V, Avishek K, Sharma V, Salotra P.

Acta Derm Venereol. 2014 Mar;94(2):242-3. doi: 10.2340/00015555-1582. No abstract available.

32.

In vitro susceptibility of Leishmania donovani to miltefosine in Indian visceral leishmaniasis.

Prajapati VK, Sharma S, Rai M, Ostyn B, Salotra P, Vanaerschot M, Dujardin JC, Sundar S.

Am J Trop Med Hyg. 2013 Oct;89(4):750-4. doi: 10.4269/ajtmh.13-0096. Epub 2013 Aug 26.

33.

Clinco-epidemiologic study of cutaneous leishmaniasis in Bikaner, Rajasthan, India.

Aara N, Khandelwal K, Bumb RA, Mehta RD, Ghiya BC, Jakhar R, Dodd C, Salotra P, Satoskar AR.

Am J Trop Med Hyg. 2013 Jul;89(1):111-5. doi: 10.4269/ajtmh.12-0558. Epub 2013 May 28.

34.

An approach for interlaboratory comparison of conventional and real-time PCR assays for diagnosis of human leishmaniasis.

Cruz I, Millet A, Carrillo E, Chenik M, Salotra P, Verma S, Veland N, Jara M, Adaui V, Castrillón C, Arévalo J, Moreno J, Cañavate C.

Exp Parasitol. 2013 Jul;134(3):281-9. doi: 10.1016/j.exppara.2013.03.026. Epub 2013 Apr 3.

PMID:
23562705
35.

Application of loop-mediated isothermal amplification assay for the sensitive and rapid diagnosis of visceral leishmaniasis and post-kala-azar dermal leishmaniasis.

Verma S, Avishek K, Sharma V, Negi NS, Ramesh V, Salotra P.

Diagn Microbiol Infect Dis. 2013 Apr;75(4):390-5. doi: 10.1016/j.diagmicrobio.2013.01.011. Epub 2013 Feb 19.

PMID:
23433714
36.

Live attenuated Leishmania donovani p27 gene knockout parasites are nonpathogenic and elicit long-term protective immunity in BALB/c mice.

Dey R, Dagur PK, Selvapandiyan A, McCoy JP, Salotra P, Duncan R, Nakhasi HL.

J Immunol. 2013 Mar 1;190(5):2138-49. doi: 10.4049/jimmunol.1202801. Epub 2013 Jan 21.

37.

Long-term efficacy of single-dose radiofrequency-induced heat therapy vs. intralesional antimonials for cutaneous leishmaniasis in India.

Bumb RA, Prasad N, Khandelwal K, Aara N, Mehta RD, Ghiya BC, Salotra P, Wei L, Peters S, Satoskar AR.

Br J Dermatol. 2013 May;168(5):1114-9. doi: 10.1111/bjd.12205.

PMID:
23298394
38.

Reliable diagnosis of post-kala-azar dermal leishmaniasis (PKDL) using slit aspirate specimen to avoid invasive sampling procedures.

Verma S, Bhandari V, Avishek K, Ramesh V, Salotra P.

Trop Med Int Health. 2013 Mar;18(3):268-75. doi: 10.1111/tmi.12047. Epub 2012 Dec 31.

39.

Validation of a simple resazurin-based promastigote assay for the routine monitoring of miltefosine susceptibility in clinical isolates of Leishmania donovani.

Kulshrestha A, Bhandari V, Mukhopadhyay R, Ramesh V, Sundar S, Maes L, Dujardin JC, Roy S, Salotra P.

Parasitol Res. 2013 Feb;112(2):825-8. doi: 10.1007/s00436-012-3212-3. Epub 2012 Dec 13.

PMID:
23239091
40.

Deletion of mitochondrial associated ubiquitin fold modifier protein Ufm1 in Leishmania donovani results in loss of β-oxidation of fatty acids and blocks cell division in the amastigote stage.

Gannavaram S, Connelly PS, Daniels MP, Duncan R, Salotra P, Nakhasi HL.

Mol Microbiol. 2012 Oct;86(1):187-98. doi: 10.1111/j.1365-2958.2012.08183.x. Epub 2012 Aug 16.

41.

Genetic typing reveals monomorphism between antimony sensitive and resistant Leishmania donovani isolates from visceral leishmaniasis or post kala-azar dermal leishmaniasis cases in India.

Subba Raju BV, Gurumurthy S, Kuhls K, Bhandari V, Schnonian G, Salotra P.

Parasitol Res. 2012 Oct;111(4):1559-68. Epub 2012 Jul 1.

PMID:
22752721
42.

Evidence for involvement of Th17 type responses in post kala azar dermal leishmaniasis (PKDL).

Katara GK, Ansari NA, Singh A, Ramesh V, Salotra P.

PLoS Negl Trop Dis. 2012;6(6):e1703. doi: 10.1371/journal.pntd.0001703. Epub 2012 Jun 19.

43.

Experimental induction of paromomycin resistance in antimony-resistant strains of L. donovani: outcome dependent on in vitro selection protocol.

Hendrickx S, Inocêncio da Luz RA, Bhandari V, Kuypers K, Shaw CD, Lonchamp J, Salotra P, Carter K, Sundar S, Rijal S, Dujardin JC, Cos P, Maes L.

PLoS Negl Trop Dis. 2012;6(5):e1664. doi: 10.1371/journal.pntd.0001664. Epub 2012 May 29.

44.

Drug susceptibility in Leishmania isolates following miltefosine treatment in cases of visceral leishmaniasis and post kala-azar dermal leishmaniasis.

Bhandari V, Kulshrestha A, Deep DK, Stark O, Prajapati VK, Ramesh V, Sundar S, Schonian G, Dujardin JC, Salotra P.

PLoS Negl Trop Dis. 2012;6(5):e1657. doi: 10.1371/journal.pntd.0001657. Epub 2012 May 22.

45.

Biomarkers of antimony resistance: need for expression analysis of multiple genes to distinguish resistance phenotype in clinical isolates of Leishmania donovani.

Kumar D, Singh R, Bhandari V, Kulshrestha A, Negi NS, Salotra P.

Parasitol Res. 2012 Jul;111(1):223-30. doi: 10.1007/s00436-012-2823-z.

PMID:
22302478
46.

Diagnosis of visceral leishmaniasis: developments over the last decade.

Srividya G, Kulshrestha A, Singh R, Salotra P.

Parasitol Res. 2012 Mar;110(3):1065-78. doi: 10.1007/s00436-011-2680-1. Epub 2011 Nov 9. Review.

PMID:
22065060
47.

Immunity to visceral leishmaniasis using genetically defined live-attenuated parasites.

Selvapandiyan A, Dey R, Gannavaram S, Lakhal-Naouar I, Duncan R, Salotra P, Nakhasi HL.

J Trop Med. 2012;2012:631460. doi: 10.1155/2012/631460. Epub 2011 Sep 6.

48.

A patient presenting with diffuse cutaneous leishmaniasis (DCL) as a first indicator of HIV infection in India.

Khandelwal K, Bumb RA, Mehta RD, Kaushal H, Lezama-Davila C, Salotra P, Satoskar AR.

Am J Trop Med Hyg. 2011 Jul;85(1):64-5. doi: 10.4269/ajtmh.2011.10-0649.

49.

Foxp3 and IL-10 expression correlates with parasite burden in lesional tissues of post kala azar dermal leishmaniasis (PKDL) patients.

Katara GK, Ansari NA, Verma S, Ramesh V, Salotra P.

PLoS Negl Trop Dis. 2011;5(5):e1171. doi: 10.1371/journal.pntd.0001171. Epub 2011 May 31.

50.

Miltefosine as an effective choice in the treatment of post-kala-azar dermal leishmaniasis.

Ramesh V, Katara GK, Verma S, Salotra P.

Br J Dermatol. 2011 Aug;165(2):411-4. doi: 10.1111/j.1365-2133.2011.10402.x.

PMID:
21561437

Supplemental Content

Loading ...
Support Center